Pharmacoeconomics of dapagliflozin in patients with type 2 diabetes mellitus with inadequate glycemic control

Abstract

Objectives. To evaluate the cost-effectiveness of dapagliflozin in combination with metformin in the treatment T2DM in comparison with glimepiride and sitagliptin also combined with metformin. Methods. Cost-utility analysis, discounting and economic feasibility assessment were performed. The results are expressed in QALY and ICUR. Pharmacoeconomic analysis showed that the application of the strategy of treatment: metformin + dapagliflozin vs metformin + sitagliptin provided 9.83 and 9.82 QALYs respectively, and the ICUR — 341.413 rubles; metformin + dapagliflozin vs metformin + glimepiride provided 9.82 and 9.47 QALY respectively, and the ICUR — 145.213 rubles. The use of combination therapy metformin + dapagliflozin is economically acceptable treatment strategy compared with combination therapy with metformin + sitagliptin and metformin + glimepiride, as ICUR indicators for dapagliflozin + metformin therapy did not exceed the cost-effectiveness threshold — «willingness to pay ratio» for Russia in any of the compared treatment strategies. Conclusion. Combination therapy metformin + dapagliflozin for treating T2DM provide good value for money for Russian state reimbursement system.

Keywords

• анализ исходов
• анализ полезности затрат
• дапаглифлозин
• математическое моделирование
• метформин
• сахарный диабет 2 типа
• фармакоэкономический анализ